Vaxart Launches Phase 1 Study of Coronavirus Vaccine Dan Weil 10/13/2020 Golden Globes biggest moments, one-dose COVID-19 vaccine, stimulus: 5 things to know Monday https://biorxiv.org/cgi/content/short/2020.09.04.283853v1, Terms The N protein was included because it would generate specific anti-viral T-cell responses against a more conserved protein than the S protein, providing for potentially better cross-protection. Could vaccine specialist Vaxart (VXRT) join the list of late disruptors?The small-cap biotech is far behind its mostly bigger competitors in the development of a COVID-19 vaccine. These findings included: The company expects to submit the Hamster Challenge Study results to a peer-reviewed journal this quarter. Vaxart's (NASDAQ:VXRT) shares plunged 58% in one trading session after one point in a clinical trial of its coronavirus vaccine candidate disappointed investors. Shares of Vaxart Inc. VXRT, -4.67% tumbled 42.9% in premarket trading on Wednesday after the company said its oral COVID-19 vaccine candidate was well-tolerated in … Vaxart’s Covid-19 vaccine program, which has already completed Phase 1 clinical trials, is unique in several respects. Vaxart Disappoints With Coronavirus Vaccine Trial Update Results from a phase 1 study show that the biotech's vaccine candidate, VXA-CoV2-1, falls short in one crucial area. Vaxart has demonstrated that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. The Company evaluated multiple vaccine candidates in its preclinical models and has chosen the lead candidate for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. We believe our room temperature stable, easy to administer oral vaccine provides a unique solution that overcomes these important difficulties. “Vaxart is developing an oral COVID-19 vaccine that will address many of the key challenges of injectable vaccines,” said Andrei Floroiu, chief executive officer of Vaxart. London, Feb. 7, 2021 (AltAfrica)-A new oral covid-19 vaccine is soon to be available as alternative to the injectable ones currently been administered in the fight against the deadly pandemic.And that’s a good news for those who have phobia for injection. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. of Use, Privacy An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. The inclusion of N protein in the vaccine candidate provides additional conserved T epitopes. Vaxart CEO defends oral COVID-19 vaccine, but shares fall 8% in morning trading. Bay Area-based Vaxart, Inc. has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.Now, the company plans to push one or more into the clinic. A portion of the results were published in Nature Medicine on Monday, January 11, 2021. “Stanford’s advanced in vitro human organoid system generated immune responses to three of our candidate vaccines,” said Sean Tucker, chief scientific officer of Vaxart. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication. Last spring Vaxart began work on an oral vaccine for Covid-19. Terms Vxart's Covid vaccine is in a small tablet and can be shipped and stored at room temperature, unlike Pfizer and Moderna's vaccines. Vaxart says Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, … Citing a report published by Vaxart on Nasdaq, Widad said Vaxart Covid-19 oral vaccine was generally well-tolerated and immunogenic as measured by multiple markers of immune response to the Covid-19 antigens. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. Vaxart announced earlier results of its Hamster Challenge Study. “The data helped us narrow our selection of a vaccine construct.” Senior authors of the paper included Dr. Mark M. Davis, Director of the Stanford Institute for Immunology, Transplantation and Infection; and Dr. Peter S. Kim, Professor of Biochemistry and former President of Merck Research Laboratories. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. (RTTNews) - Shares of Vaxart Inc. (VXRT) have gained an impressive 265 percent so far this year on hopes of a vaccine for the novel coronavirus. Small biotech Vaxart on Tuesday said it dosed its first test subjects with an oral Covid-19 vaccine tablet, sparking VXRT stock to early double-digit … In early 2020, Vaxart established a collaboration with researchers from Stanford University School of Medicine to assess its COVID-19 vaccine candidates in human lymphoid organoid culture. Policy, A 4- to 5-fold log reduction in lung viral load in hamsters that received two oral vaccine doses, as compared to non-vaccinated animals.       Â, Potent induction of antibody response, with serum IgG antibody titers above 10,000 in hamsters that received two oral vaccine doses.          Â. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models, An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine, Data from Vaxart’s Phase I COVID-19 trial expected to be released next week. It contains an adenovirus called Ad5 (the same viral vector in CanSinoBio’s vaccine and in Russia’s Sputnik V). © 2021 Vaxart, Inc., All rights reserved. SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”  The manuscript describes the pre-clinical development of a SARS-CoV-2 (COVID-19) vaccine based on Vaxart’s oral adenovirus platform and is available on an online preprint server at https://biorxiv.org/cgi/content/short/2020.09.04.283853v1. Shares of Vaxart cratered 58% on Feb. 3 after early preliminary trial data showed that its oral COVID-19 vaccine did not produce neutralizing antibodies in “most subjects.” “Vaxart is developing an oral COVID-19 vaccine that will address many of the key challenges of injectable vaccines,” said Andrei Floroiu, chief executive officer of Vaxart. Vaxart is not responsible for the contents of third-party websites. “Our oral vaccine could help fight the COVID-19 epidemic globally because it is stable at room-temperature making it easier to transport, store, and administer than injectables. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its COVID-19 vaccine candidate and preclinical or clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations regarding the timing and nature of future announcements, including those related to clinical trials and results of preclinical studies; Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for coronaviruses; the potential applicability of results seen in our preclinical studies or trials to those that may be seen in human studies or clinical trials; the expected role of mucosal immunity in blocking transmission of COVID-19; and Vaxart’s expectations with respect to the effectiveness of its products or product candidates. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAAST TM oral vaccines platform. 03, 2021 9:49 AM ET Vaxart, Inc. (VXRT) By: Jonathan M Block, SA News Editor 22 Comments. Immunization with the vaccine candidate induced IgA response in the lungs of animals, which is indicative of a mucosal immune response. This press release contains forward-looking statements that involve substantial risks and uncertainties. June 26, 2020 - Vaxart, Inc. announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by Operation Warp Speed, a new national program to provide substantial quantities of safe, effective vaccines … SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration with prominent Stanford University scientists on COVID-19 vaccine candidates. Vaxart (NASDAQ: VXRT) started last month on a sour note. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. © 2021 Vaxart, Inc., All rights reserved. Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to $9.85. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law. Vaxart (NASDAQ:VXRT) isn't nearly as far along in clinical testing of its COVID-19 vaccine candidate, VXA-CoV2-1. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. Importantly, while systemic immunity is important for controlling the development of illness, it has been suggested that mucosal immunity may be essential for blocking transmission which will be crucial for an effective vaccine campaign. Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission, Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines. As we continue to learn more about COVID-19, there is a growing body of evidence that mucosal immunity may become a key factor for the development of an efficacious vaccine. Vaxart said the vaccine generated a type of T … Based on these results, we believe our vaccines are ideal to protect against mucosal respiratory viruses such as SARS-CoV-2, the virus that causes COVID-19.” In January 2020, Vaxart … The phase 1 trial data for its investigational coronavirus vaccine was disappointing, and its … In early 2020, Vaxart established a collaboration with researchers from Stanford University School of Medicine to assess its COVID-19 vaccine candidates in human lymphoid organoid culture. We look forward to advancing our COVID-19 vaccine candidate into the clinic.”, Sean Tucker, Ph.D., chief scientific officer of Vaxart, commented, “The data from these studies suggest that our vaccine candidate is capable of inducing immunogenicity on three levels: first, to induce potent serum neutralizing antibodies to the viral S protein, second to induce a mucosal immune response, and third to induce T cell responses.